You Are Here    News

News

Featured news from BHIVA

New Sexually Transmitted Infection figures show rapid increases among gay men
by Admin, 2015-06-23 18:15

Vacancies on the UK National Screening Committee
by Admin, 2015-06-23 11:15

Susie Parsons obituary
by Admin, 2015-06-22 18:25


View more news from BHIVA



HIV-related news from NAM

Daclatasvir plus sofosbuvir cures HCV for most people with HIV and HCV co-infection in French compassionate use programme
by Liz Highleyman, 2015-08-03 08:50
Interferon-free treatment using daclatasvir (Daklinza) and sofosbuvir (Sovaldi), with or without ribavirin, was well-tolerated and produced sustained virological response rates of 95-100% for people with HIV and HCV co-infection and advanced liver disease, according to a presentation at the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last week in

Interferon-free hepatitis treatment is highly effective for people with HIV and HCV co-infection in three studies
by Liz Highleyman, 2015-07-29 18:00
Three different interferon-free regimens – sofosbuvir/ledipasvir, AbbVie's 3D regimen and grazoprevir/elbasvir – were well-tolerated and cured more than 90% of participants with HIV and HCV co-infection in three clinical trials, confirming that HIV-positive people can respond as well as HIV-negative people to modern hepatitis C treatment, according to a set of reports presented at the

Intensification of antiretroviral therapy reduces risk of late-term mother-to-child HIV transmission
by Carole Leach-Lemens, 2015-07-29 17:00
Maternal and infant antiretroviral therapy (ART) intensification is very effective in preventing HIV transmission during labour and birth in pregnant women with HIV in Thailand who present late for care (with less than eight weeks of standard ART), Marc Lallemant told the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015)

Implant and injectable hormonal contraception most effective methods for women living with HIV
by Carole Leach-Lemens, 2015-07-29 13:10
Hormonal contraceptive methods are highly effective in reducing the risk of pregnancy in women living with HIV whether on antiretroviral therapy (ART) or not, according to an evaluation involving over 5000 women, Maria Pyra told participants at the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, last

Liver fibrosis regression after hepatitis C treatment linked to reduced complications and death in people with HIV and HCV co-infection
by Liz Highleyman, 2015-07-29 11:10
People with HIV and HCV co-infection, with liver cirrhosis, who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from liver-related causes – and in some cases fibrosis regression is beneficial even in the absence of a cure – according to a

Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health
by Liz Highleyman, 2015-07-28 12:30
People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable viral load and saw improvements in liver function biomarkers and bone density, according to a pair of studies presented at the Eighth International AIDS Society Conference on

Raltegravir appears to prevent mother-to-child HIV transmission during late pregnancy
by Liz Highleyman, 2015-07-28 12:20
Combination antiretroviral therapy containing the integrase inhibitor raltegravir (Isentress) appears safe and effective and may be an attractive option for treatment for pregnant women with HIV – and potentially their infants – to prevent perinatal HIV transmission, according to study findings presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention

PrEP demo project finds the people at highest HIV risk generally take PrEP most consistently
by Gus Cairns, 2015-07-27 19:30
An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the United States has found generally high retention and adherence rates, with the highest adherence among those at the highest risk of HIV, the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) heard last week. However, some groups appeared to

Vancouver's treatment as prevention success is also due to harm reduction and addiction treatment
by Roger Pebody, 2015-07-27 19:10
“We talk a lot about the success of treatment as prevention in Vancouver, but we always need to make sure people understand that this requires an integration of various approaches,” Dr Evan Wood of the University of British Columbia said in a plenary presentation to the Eighth International AIDS Society Conference (IAS 2015) in